Can Electronic Patient-Reported Outcome (ePRO) Data Be Changed or Not?

Source: EClinCloud. Author: EClinCloud.

Can ePRO data be changed?
The EMA's recently issued "Guideline on computerised systems and electronic data in clinical trials" draft1 states:
Data clarification procedures initiated by the sponsor or vendor are not acceptable, even with a legitimate justification (regardless of whether they are mentioned in the study protocol)—for example, when a subject discovers that data were not entered correctly.
This aligns with the PRO guidance previously issued by the FDA in 20092, which states:
Sponsors should avoid:
● Complete control of the source file by the sponsor alone;
● Clinical researchers being unable to maintain and ensure the accuracy of ePRO data.

ePRO data cannot be changed unilaterally by the sponsor!
However, it is inevitable that a subject may accidentally tap the wrong option and enter incorrect data; therefore, to ensure that the data are completely accurate, a data correction procedure is essential.

Oops! Tapped the wrong one!
Regulatory guidance and ICH GCP guidelines indicate that sound procedures must be established to allow the investigator to modify data when necessary, such as a Data Change Request (DCR) procedure.
So the question is: when does changing data improve data reliability, and when does it undermine it? For the same patient, is a change made at the time of the assessment as reliable as a change made 1 month after the assessment ends?

Clearly not.
A sound procedure needs to take the following key factors into account:
1
Assess the risk level of the data to be modified.
2
Define the process for DCR review.
3
Maintain an audit trail for data changed through the DCR procedure.
Audit trail records must be created to ensure that data changes made through the DCR procedure are supported by sufficient evidence.
4
Provide instructions for the DCR procedure.
Clear documentation explaining the DCR review procedure should be provided to investigators prior to their participation in the study.
The final decision on whether to change data rests with the study site, and the study site's decision must be fully respected. A rigorous procedure can help the study site fulfill its responsibility for source data. In addition, maintaining data integrity and reliability is also critical to passing regulatory review.
References
1. EMA (2021). Draft guideline on computerised systems and electronic data in clinical trials. https://www. ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-computerised-systems- electronic-data-clinical-trials_en.pdf
2. FDA (2009). Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported- outcome-measures-use-medical-product-development-support-labeling-claims
Article source: Signant Health
About EClinCloud
EClinCloud is a healthcare and life-sciences technology company based in China and serving the globe. Driven by science and medicine, and with the mission to "bring effective treatments to patients through technological innovation," it combines digital technology with life-sciences data to build an end-to-end digital clinical trial cloud platform and provide technical solutions for clinical endpoint assessment, helping pharmaceutical companies and research institutions in China and abroad improve R&D efficiency, accelerate bringing drugs and medical devices to market, and benefit countless patients.



